Suppr超能文献

响应胆固醇吸收抑制而选择性代偿性诱导肝脏HMG-CoA还原酶

Selective compensatory induction of hepatic HMG-CoA reductase in response to inhibition of cholesterol absorption.

作者信息

Ness Gene C, Holland Reed C, Lopez Dayami

机构信息

Department of Biochemistry and Molecular Biology, College of Medicine, 12901 Bruce B. Downs Boulevard, University of South Florida, Tampa, FL 33612, USA.

出版信息

Exp Biol Med (Maywood). 2006 May;231(5):559-65. doi: 10.1177/153537020623100510.

Abstract

The effect of the potent inhibitor of cholesterol absorption, ezetimibe, on serum cholesterol levels was tested in diabetic and thyroidectomized male Sprague-Dawley rats. Feeding diets supplemented with 1% cholesterol to the diabetic rats raised serum cholesterol levels from 132 to 514 mg/dl while decreasing hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase protein and mRNA levels. Addition of 10 mg/kg/day of ezetimibe to the diets of these animals lowered the serum cholesterol level to 90 mg/dl and produced a large compensatory increase in hepatic HMG-CoA reductase protein without significantly increasing mRNA levels, indicating a post-transcriptional effect. Hepatic LDL receptor protein levels in these diabetic rats were unaffected by ezetimibe treatment. In contrast, ezetimibe treatment of these young normal Sprague-Dawley rats, known to express high levels of hepatic HMG-CoA reductase, did not lower serum cholesterol levels. In thyroidectomized rats, dietary cholesterol increased serum cholesterol levels from 116 to 135 mg/dl and ezetimibe treatment lowered these elevated cholesterol levels to 85 mg/dl. Cholesterol feeding of thyroidectomized rats severely reduced hepatic HMG-CoA reductase protein, while ezetimibe treatment restored reductase protein to normal levels. Again, hepatic LDL receptor protein levels were unaffected by ezetimibe treatment of cholesterol-fed thyroidectomized rats. The data demonstrate that the cholesterol absorption inhibitor ezetimibe profoundly lowers serum cholesterol levels in animals expressing very low rates of hepatic cholesterol synthesis and produces large compensatory increases in hepatic HMG-CoA reductase expression without significantly affecting expression of hepatic LDL receptors. This indicates that ezetimibe should be most effective in lowering serum cholesterol levels in people with low rates of cholesterol synthesis/high rates of cholesterol absorption.

摘要

在糖尿病和甲状腺切除的雄性斯普拉格 - 道利大鼠中测试了强效胆固醇吸收抑制剂依泽替米贝对血清胆固醇水平的影响。给糖尿病大鼠喂食添加1%胆固醇的饲料,可使血清胆固醇水平从132毫克/分升降至514毫克/分升,同时降低肝脏3 - 羟基 - 3 - 甲基戊二酰辅酶A(HMG - CoA)还原酶蛋白和mRNA水平。在这些动物的饲料中添加10毫克/千克/天的依泽替米贝,可使血清胆固醇水平降至90毫克/分升,并使肝脏HMG - CoA还原酶蛋白大幅代偿性增加,而mRNA水平无显著升高,表明存在转录后效应。这些糖尿病大鼠的肝脏低密度脂蛋白受体蛋白水平不受依泽替米贝治疗的影响。相比之下,对已知表达高水平肝脏HMG - CoA还原酶的年轻正常斯普拉格 - 道利大鼠进行依泽替米贝治疗,并未降低血清胆固醇水平。在甲状腺切除的大鼠中,饮食中的胆固醇使血清胆固醇水平从116毫克/分升升至135毫克/分升,依泽替米贝治疗可将这些升高的胆固醇水平降至85毫克/分升。给甲状腺切除的大鼠喂食胆固醇会严重降低肝脏HMG - CoA还原酶蛋白,而依泽替米贝治疗可使还原酶蛋白恢复至正常水平。同样,在喂食胆固醇的甲状腺切除大鼠中,依泽替米贝治疗对肝脏低密度脂蛋白受体蛋白水平无影响。数据表明,胆固醇吸收抑制剂依泽替米贝可显著降低肝脏胆固醇合成率极低的动物的血清胆固醇水平,并使肝脏HMG - CoA还原酶表达大幅代偿性增加,而对肝脏低密度脂蛋白受体的表达无显著影响。这表明依泽替米贝在降低胆固醇合成率低/胆固醇吸收率高的人群的血清胆固醇水平方面应该最有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验